Table 3.

Prognostic factors for overall survival in the imatinib combined with hepatic resection group (IM+HR) and imatinib combined with radiofrequency ablation or transarterial chemoembolization group (IM+RFA/TACE).

Variables	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Sex (male vs. female)	1.235 (0.327–4.658)	0.756
Age (≤60 vs. >60 years)	0.234 (0.070–0.783)	0.018	0.395 (0.107–1.451)	0.162
Primary Sites (stomach vs. others)	2.077 (0.631–6.838)	0.239
Metastatic phase (metachronous vs. synchronous)	0.778 (0.237–2.552)	0.678
Number of Metastases (≤3 vs. >3)	0.511 (0.156–1.674)	0.267
Largest diameter of metastases (≤3 vs. >3 cm)	1.305 (0.398–4.281)	0.661
Extrahepatic metastases (no vs. yes)	0.358 (0.109–1.176)	0.090	0.538 (0.148–1.955)	0.346
IM response before surgical treatment (PR+SD+NA vs. PD)	0.540 (0.164–1.772)	0.310
Status after surgical treatment (NED vs. non-NED)	0.065 (0.008–0.511)	0.009	0.099 (0.012–0.835)	0.034
Therapy (IM+HR vs. IM+RFA/TACE)	0.308 (0.094–1.012)	0.052	0.625 (0.184–2.119)	0.450

HR, hazard ratio.

NA, not applicable; NED, no evidence of disease; PD, progressive disease; PR, partial response; SD, stable disease.